Monthly Prescribing Reference

Brixadi Now Available for Weekly or Monthly Administration to Treat Opioid Use Disorder

Credit: Braeburn. Brixadi (weekly) and Brixadi (monthly) are different formulations. Brixadi ® (buprenorphine) extended-release subcutaneous injection is now available for the treatment of moderate to ...
Monthly Prescribing Reference

Brixadi Gets Tentative FDA Approval for Opioid Use Disorder

Braeburn announced that the Food and Drug Administration (FDA) has tentatively approved Brixadi (buprenorphine) extended-release weekly and monthly injections for the treatment of moderate to severe ...
ksn.com

Braeburn's BRIXADI™ (buprenorphine) Extended-Release Subcutaneous Injection (CIII) Receives FDA Approval for Moderate to Severe Opioid Use Disorder

BRIXADI is the first and only long-acting buprenorphine injectable with both weekly and monthly doses. Patients currently on a transmucosal buprenorphine-containing product can be switched to an ...
WTNH

Camurus announces FDA approval of Brixadi™ for the treatment of moderate to severe opioid use disorder

LUND, Sweden, May 24, 2023 /PRNewswire/ -- Camurus (NASDAQ STO: CAMX) today announces that the US Food and Drug Administration (FDA) has approved Brixadi™ (buprenorphine) extended release injection ...
Nasdaq

Braeburn Initiates Court Proceedings to Overturn Exclusivity and Seeks Immediate Market Approval of Brixadi(TM) in the US

LUND, Sweden, April 9, 2019 /PRNewswire/ -- Camurus' (NASDAQ STO: CAMX) US partner, Braeburn Inc., today announced that the company today will file an action in federal district court for the District ...
Daily Local News

FDA Accepts Braeburn’s New Drug Application Resubmission for BRIXADITM (buprenorphine) Extended-Release Subcutaneous Injection for Moderate to Severe Opioid Use Disorder

PLYMOUTH MEETING, Pa., June 26, 2021 /PRNewswire/ — Braeburn announces that the New Drug Application (NDA) for BRIXADI (buprenorphine) extended-release weekly and monthly injection for subcutaneous ...
PharmiWeb

Camurus Announces That FDA Grants Braeburn's Citizen Petition, Eliminating the Risk of Further Blocking of Brixadi(TM) From the US market

LUND, Sweden, Nov. 8, 2019 /PRNewswire/ -- Camurus AB (NASDAQ STO: CAMX) today announces that the U.S. Food and Drug Administration (FDA) has granted Camurus' US partner Braeburn's request (through ...